The report aims at helping the international community to address the toll that illicit drug production, trafficking and consumption continues to take on all our societies, by providing a global overview and analysis of developments.
This document develops core arguments for why people who inject drugs should be included in national treatment guidelines and programmes for chronic HCV infection – from both public health and human rights perspectives.
This report outlines the DEA's inability to exercise its responsibilities in a fair and impartial manner or to act in accord with the scientific evidence.
This report finds that at a population level most migrants in the EU/EEA are healthy, and are only more affected by certain diseases such as HIV and tuberculosis.
This report describes the challenges in West Africa and the policies the region must adopt to prevent drug trafficking, production and consumption from undermining states and societies, and destroying lives.
The report highlights the failures related to the international scheduling of controlled drugs, and proposes key recommendations to ensure a system based on health and evidence.
This briefing clarifies the extent of Portugal’s achievement, and debunks some of the erroneous claims made about the country’s innovative approach to drugs.
The EU needs to improve its knowledge of drug markets and criminal activities in beneficiary countries, to ensure their projects are sensitive to the potentially counterproductive effects on organised crime and the drug trade in West Africa.
This study aims to estimate the number of people with chronic HCV infection in England that are treated and assess the impact and costs of increasing treatment uptake.
